Company intelligence / Profile preview

FluoGuide

Ownership: Public · FLUO
Employees: ~8
Development stage: Other

Overview

FluoGuide’s lead product, FG001, has demonstrated clinical benefit in aggressive brain cancers by enabling surgeons to remove additional tumor tissue in all patients studied. It has also shown efficacy in lung and head & neck cancers. The company’s approach reduces local recurrence risk, surgical complications, and healthcare costs. FG001 also functions as a photosensitizer with potential applications in photothermal and photodynamic therapy. Strategic partnerships include collaborations with Intuitive Surgical for robotic-assisted surgery.

Therapeutic areas: Oncology
Modalities: Small moleculeDevice
Industry: Biotech

Drug pipeline

2 assets

FG001

1 more asset in the full pipeline.

Request access →

Partnerships

Intuitive Surgical (robotic-assisted surgery)laser system manufacturerRigshospitaletUniversity of Copenhagen

Beyond the preview

Go deeper on FluoGuide.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FluoGuide.

Explore the full profile